Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16‐week real‐life experience during the COVID‐19 pandemic in Italy. Issue 5 (25th June 2021)

• Record Type: Journal Article
• Authors: Stingeni, Luca; Hansel, Katharina; Antonelli, Elettra; Bello, Giacomo Dal; Patruno, Cataldo; Napolitano, Maddalena; Fabbrocini, Gabriella; Grieco, Teresa; Pellacani, Giovanni; Fargnoli, Maria Concetta; Esposito, Maria; Piras, Viviana; Zucca, Myriam; Girolomoni, Giampiero
• Is Part Of: Dermatologic therapy. Volume 34:Issue 5(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-06-25
• Subjects: adolescents -- atopic dermatitis -- COVID‐19 -- dupilumab -- real‐world; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.15035
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Dupilumab showed significant improvement of adolescent atopic dermatitis (AD) signs and symptoms in clinical trials, with a good safety profile. Herein we report the real‐word effectiveness and safety of dupilumab in adolescents with moderate to severe AD from January to October 2020, during the COVID‐19 pandemic in Italy. All patients had a diagnosis of AD for a mean [SD] 12.8 [3.1] years. Baseline demographics, AD characteristics (EASI, cDLQI, NRS itch score, NRS sleep loss score) at baseline and week 16, and safety data were collected. Nineteen patients (52.6% men; mean [SD] age, 15.6 [1.4] years [range, 13–17 years]) were included in the analysis. All patients reached EASI‐50 and 78.9% EASI‐75, especially in those with EASI≥30 and BMI < 25 at baseline, with marked reduction for cDLQI (77.4%), NRS itch score (5.9 point), and NRS sleep loss score (87.5%). One patient contracted asymptomatic SARS‐CoV‐2 infection and 1 developed mild conjuntivitis, without stopping dupilumab. In this real‐word experience the effectiveness of dupilumab was excellent and resulted higher than that observed in clinical trials, with a good safety profile during COVID‐19 pandemic.